FDA approves Bristol Myers' oral heart disease drug
FILE PHOTO: A woman holds test tube in front of displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration(Reuters) -Bristol Myers Squibb said on Thursday the U.S. Food and Drug Administration (FDA) approved its oral heart disease drug Mavacamten, making it the first cardiac myosin inhibitor to be permitted for use in the country. Mavacamten, […]
» Read more